Pharmac have recently approved funding for Hepatitis C treatment ViekiraPAK and ViekiraPAK/RBV, and these are listed on the Pharmaceutical Schedule. This means that treatment is funded for all patients with Hepatitis C virus genotype 1. Harvoni is available for patients who meet the Pharmac special authority criteria. ACC clients are eligible for the Hepatitis C treatments listed in the Pharmaceutical Schedule.
ACC may consider funding Hepatitis C treatments for our covered clients who do not meet the criteria in the Pharmaceutical Schedule. You can check the Pharmaceutical Schedule funding criteria on the Pharmac website.
To apply to ACC for funding for this treatment, or if you have any questions, please contact Angela Carter by:
ACC Claims Manager
Treatment Assessment Centre
PO Box 408
If you have any questions, you can contact Angela:
by phone – (03) 470 5877
by email – email@example.com